|
WO2019217307A1
(en)
|
2018-05-07 |
2019-11-14 |
Mirati Therapeutics, Inc. |
Kras g12c inhibitors
|
|
ES3004338T3
(en)
|
2018-09-10 |
2025-03-12 |
Mirati Therapeutics Inc |
Combination therapies
|
|
KR102871791B1
(ko)
|
2018-09-10 |
2025-10-15 |
미라티 테라퓨틱스, 인크. |
병용 요법
|
|
JP2022500385A
(ja)
|
2018-09-10 |
2022-01-04 |
ミラティ セラピューティクス， インコーポレイテッド |
組み合わせ療法
|
|
WO2020055761A1
(en)
|
2018-09-10 |
2020-03-19 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
TWI831855B
(zh)
|
2018-10-26 |
2024-02-11 |
日商大鵬藥品工業股份有限公司 |
新穎吲唑化合物或其鹽
|
|
CA3112129A1
(en)
|
2018-12-05 |
2020-06-11 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
JP7592601B2
(ja)
|
2019-01-10 |
2024-12-02 |
ミラティ セラピューティクス， インコーポレイテッド |
Ｋｒａｓ ｇ１２ｃ阻害剤
|
|
CA3148745A1
(en)
|
2019-08-29 |
2021-03-04 |
Xiaolun Wang |
Kras g12d inhibitors
|
|
US12122787B2
(en)
|
2019-09-20 |
2024-10-22 |
Shanghai Jemincare Pharmaceuticals Co., Ltd |
Fused pyridone compound, and preparation method therefor and use thereof
|
|
CN114761012B
(zh)
|
2019-09-24 |
2025-03-21 |
米拉蒂治疗股份有限公司 |
组合疗法
|
|
CA3158793A1
(en)
|
2019-10-28 |
2021-05-06 |
Merck Sharp & Dohme Corp. |
Small molecule inhibitors of kras g12c mutant
|
|
WO2021106230A1
(ja)
|
2019-11-29 |
2021-06-03 |
大鵬薬品工業株式会社 |
新規なフェノール化合物又はその塩
|
|
WO2021120045A1
(en)
|
2019-12-18 |
2021-06-24 |
InventisBio Co., Ltd. |
Heterocyclic compounds, preparation methods and uses thereof
|
|
KR20220130126A
(ko)
|
2019-12-20 |
2022-09-26 |
미라티 테라퓨틱스, 인크. |
Sos1 억제제
|
|
CN113105448A
(zh)
*
|
2020-01-13 |
2021-07-13 |
苏州泽璟生物制药股份有限公司 |
芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用
|
|
CN114671866A
(zh)
*
|
2020-12-25 |
2022-06-28 |
苏州泽璟生物制药股份有限公司 |
芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用
|
|
EP4092026A4
(en)
*
|
2020-01-13 |
2024-03-06 |
Suzhou Zelgen Biopharmaceutical Co., Ltd. |
ARYL OR HETEROARYL PYRIDONE OR PYRIMIDINE DERIVATIVES, PRODUCTION METHOD AND USE THEREOF
|
|
CN112159405B
(zh)
*
|
2020-02-04 |
2021-09-14 |
广州必贝特医药技术有限公司 |
吡啶并嘧啶酮类化合物及其应用
|
|
WO2023205701A1
(en)
|
2022-04-20 |
2023-10-26 |
Kumquat Biosciences Inc. |
Macrocyclic heterocycles and uses thereof
|
|
CN114901663B
(zh)
*
|
2020-03-02 |
2024-07-02 |
上海喆邺生物科技有限公司 |
一类芳香杂环类化合物及其在药物中的应用
|
|
WO2021249563A1
(zh)
*
|
2020-06-12 |
2021-12-16 |
苏州泽璟生物制药股份有限公司 |
芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用
|
|
KR20230042600A
(ko)
|
2020-06-18 |
2023-03-28 |
레볼루션 메디슨즈, 인크. |
Ras 억제제에 대한 획득된 저항성을 지연, 예방, 및 치료하는 방법
|
|
CN114075195B
(zh)
*
|
2020-08-21 |
2026-04-28 |
广东东阳光药业股份有限公司 |
嘧啶酮衍生物及其在药物中的应用
|
|
CA3187757A1
(en)
|
2020-09-03 |
2022-03-24 |
Ethan AHLER |
Use of sos1 inhibitors to treat malignancies with shp2 mutations
|
|
US12286431B2
(en)
|
2020-09-11 |
2025-04-29 |
Mirati Therapeutics, Inc. |
Crystalline forms of a KRas G12C inhibitor
|
|
MX2023003338A
(es)
|
2020-09-23 |
2023-06-14 |
Erasca Inc |
Piridonas y pirimidonas tricíclicas.
|
|
CN116390919B
(zh)
*
|
2020-11-24 |
2025-12-23 |
杭州多域生物技术有限公司 |
一种芳香化合物、其制备方法及应用
|
|
CA3200164A1
(en)
*
|
2020-11-26 |
2022-06-02 |
Qingxin Liu |
Salt and crystal form of nitrogen-containing heterocyclic derivative, preparation method therefor and application thereof
|
|
US12398154B2
(en)
|
2020-12-15 |
2025-08-26 |
Mirati Therapeutics, Inc. |
Azaquinazoline pan-KRas inhibitors
|
|
EP4262803A4
(en)
|
2020-12-16 |
2025-03-12 |
Mirati Therapeutics, Inc. |
Tetrahydropyridopyrimidine pan-kras inhibitors
|
|
US20230107642A1
(en)
|
2020-12-18 |
2023-04-06 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
|
KR20230088804A
(ko)
*
|
2020-12-21 |
2023-06-20 |
아비스코 테라퓨틱스 컴퍼니 리미티드 |
마크로시클릭 k-ras g12c 억제제, 이의 제조 방법 및 용도
|
|
US20240189313A1
(en)
*
|
2021-03-11 |
2024-06-13 |
InventisBio Co., Ltd. |
Solid dispersions
|
|
WO2022266206A1
(en)
|
2021-06-16 |
2022-12-22 |
Erasca, Inc. |
Kras inhibitor conjugates
|
|
MX2024000965A
(es)
|
2021-07-27 |
2024-02-09 |
Toray Industries |
Medicamento para el tratamiento y/o prevencion de cancer.
|
|
EP4395769A1
(en)
|
2021-09-01 |
2024-07-10 |
Novartis AG |
Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers
|
|
WO2023190748A1
(ja)
|
2022-03-31 |
2023-10-05 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
腫瘍治療用医薬組成物
|
|
CN117462553A
(zh)
*
|
2022-07-20 |
2024-01-30 |
益方生物科技(上海)股份有限公司 |
药物组合产品以及组合疗法
|
|
WO2024081674A1
(en)
|
2022-10-11 |
2024-04-18 |
Aadi Bioscience, Inc. |
Combination therapies for the treatment of cancer
|
|
AU2024241633A1
(en)
|
2023-03-30 |
2025-11-06 |
Revolution Medicines, Inc. |
Compositions for inducing ras gtp hydrolysis and uses thereof
|
|
CN120813358A
(zh)
|
2023-04-06 |
2025-10-17 |
卫材R&D管理有限公司 |
用于治疗肿瘤的药物组合物
|
|
CN121712509A
(zh)
|
2023-05-04 |
2026-03-20 |
锐新医药公司 |
用于ras相关疾病或病症的组合疗法
|
|
US20250049810A1
(en)
|
2023-08-07 |
2025-02-13 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
IL327380A
(en)
|
2023-09-29 |
2026-05-01 |
D3 Bio Wuxi Co Ltd |
Combinations of WX-001 or its derivatives with KRAS G12C inhibitor for use in cancer treatment
|
|
IL327306A
(en)
|
2023-10-12 |
2026-05-01 |
Revolution Medicines Inc |
Macrocyclic RAS inhibitors
|
|
WO2025085748A1
(en)
|
2023-10-20 |
2025-04-24 |
Merck Sharp & Dohme Llc |
Small molecule inhibitors of kras proteins
|
|
WO2025171296A1
(en)
|
2024-02-09 |
2025-08-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025240847A1
(en)
|
2024-05-17 |
2025-11-20 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025242126A1
(zh)
*
|
2024-05-22 |
2025-11-27 |
上海正大天晴医药科技开发有限公司 |
一种药物组合及其应用
|
|
WO2025255438A1
(en)
|
2024-06-07 |
2025-12-11 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2025265060A1
(en)
|
2024-06-21 |
2025-12-26 |
Revolution Medicines, Inc. |
Therapeutic compositions and methods for managing treatment-related effects
|
|
WO2026006747A1
(en)
|
2024-06-28 |
2026-01-02 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026015796A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015801A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015825A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Use of ras inhibitor for treating pancreatic cancer
|
|
WO2026015790A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026050446A1
(en)
|
2024-08-29 |
2026-03-05 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026072904A2
(en)
|
2024-09-26 |
2026-04-02 |
Revolution Medicines, Inc. |
Compositions and methods for treating lung cancer
|
|
WO2026090116A2
(en)
|
2024-10-21 |
2026-04-30 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026090245A1
(en)
|
2024-10-22 |
2026-04-30 |
Revolution Medicines, Inc. |
Use of ras inhibitors for treating cancer
|
|
US20260108528A1
(en)
|
2024-10-22 |
2026-04-23 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|